Compugen Achieves Third Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer
11 Diciembre 2015 - 8:06AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug
discovery company, announced today that it has achieved the
third preclinical milestone pursuant to its cancer immunotherapy
collaboration with Bayer HealthCare (Bayer). The collaboration
provides for the research, development, and commercialization of
antibody-based cancer therapeutics against two novel
Compugen-discovered immune checkpoint regulators, CGEN-15001T
and CGEN-15022.
The milestone payment being announced today, and the two
previous milestone payments received by Compugen under the
collaboration, all relate to CGEN-15001T, which is the more
advanced of the two programs. This program, for which US and EU
patents have been granted to Compugen, is demonstrating encouraging
functional activity in preclinical models of cancer immunotherapy.
Upon achievement of this third milestone, this program has now been
transferred to Bayer’s full control for further preclinical and
clinical development activities, and worldwide commercialization,
under milestone and royalty bearing licenses from Compugen.
CGEN-15022, which is at an earlier stage than CGEN-15001T,
continues under the joint preclinical research program, with
results from these activities providing promising support for the
target’s ability to modulate immune response via a potentially
novel mechanism of action, and the target is currently being
further characterized regarding its role in anti-cancer immune
response.
“We are very pleased to have reached this milestone, which marks
the successful completion of the joint pre-clinical work for one of
the two immuno-oncology candidates under the Bayer/Compugen
collaboration. Now that this program is transferred to Bayer for
further preclinical and clinical development, we view this as
further testimony to the power of drug discovery via computational
predictions,” said Anat Cohen-Dayag, Ph.D., President and Chief
Executive Officer of Compugen. “Since the very beginning of this
partnership, there has been continuing progress on both programs,
including a growing understanding of target biology, in addition to
the advancement of therapeutic candidates in a joint preclinical
research program. Each program presents a distinctive
differentiation profile compared to known checkpoints, providing
potentially different mechanisms of action and expanded
opportunities for cancer treatment. Both partners are excited by
the potential of the two programs as they progress towards
potential novel therapeutics for cancer immunotherapy.”
For additional information, please refer to Compugen’s recent
Form 6-K filing.
About the Compugen/Bayer HealthCare Agreement
In August 2013, Compugen and Bayer HealthCare entered into a
collaboration and license agreement for the development and
commercialization of antibody-based cancer immune therapeutics
against two novel Compugen-discovered immune checkpoint regulators,
CGEN-15022 and CGEN-15001T. Compugen received an upfront payment of
$10 million and is eligible to receive over $500 million in
potential milestone payments for both checkpoint programs, plus an
additional $30 million of potential milestone payments associated
with joint preclinical research for the two programs.
About Cancer Immunotherapy
The latest cancer immunotherapies have demonstrated impressive
clinical benefit, even for end-stage patients with
difficult-to-treat tumors such as metastatic melanoma and non-small
cell lung cancer. Unlike conventional cancer therapies, which act
by directly targeting the cancer cells, often resulting in only
transient clinical responses as cancer cells become resistant,
clinical responses to cancer immunotherapy tend to be durable,
sometimes resulting in dramatic long-term survival and the absence
of resistance or recurrences.
About Compugen
Compugen is a leading drug discovery company utilizing its
broadly applicable predictive discovery infrastructure to identify
novel drug targets and develop first-in-class biologics. The
Company’s current pipeline primary focus is on immune checkpoint
target candidates discovered by the Company, potentially providing
the basis for a next wave of therapeutics for cancer immunotherapy.
Compugen’s business model is based on selectively entering into
collaborations for its novel targets and drug product candidates at
various stages of research and development under revenue-sharing
agreements. The Company is headquartered in Tel Aviv, Israel, with
R&D facilities in Tel Aviv and South San Francisco. At the US
facilities, monoclonal antibody therapeutic candidates are
discovered and developed against the Company’s novel target
candidates. For additional information, please visit Compugen's
corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as “will,” “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Among these risks:
Compugen’s business model is substantially dependent on entering
into collaboration agreements with third parties and may not be
successful in generating revenues, and the development and
commercialization of therapeutic candidates involve many inherent
risks, including failure to progress to clinical trials or, if they
progress to or enter clinical trials, failure to receive regulatory
approval. These and other factors are more fully discussed in the
"Risk Factors" section of Compugen’s most recent Annual Report on
Form 20-F as filed with the Securities and Exchange Commission as
well as other documents that may be subsequently filed by Compugen
from time to time with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Compugen’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151211005383/en/
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@cgen.com
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024